Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Pharmaceuticals has obtained an order from an administrative law judge in Florida that the inclusion of Levothyroxine sodium on the state's negative drug formulary is an invalid exercise of legislative authority and that the product should be removed from the negative formulary.
Subscribe to our email newsletter
Mylan will make its products available to pharmacies in Florida as soon as motions and procedural steps surrounding its removal from the negative formulary are satisfied. Florida’s Board of Medicine and Board of Pharmacy voted not to appeal the January 28, 2008, order; Abbott Laboratories has filed a formal appeal. Levothyroxine sodium is indicated for the treatment of hypothyroidism and pituitary TSH suppression.
Heather Bresch, COO of Mylan, said: “The state will benefit from tens of millions of dollars in savings as a result of this decision, and we are extremely pleased that the judge on this case saw through the brand company’s baseless tactics to limit consumer access to affordable and effective medications.”